Serum MBP immunoreactivity and immunoglobulin level as markers of tumour type.
Forty three patients, admitted to the department of Neurological Surgery for management of central nervous system tumours, were studied pre-operatively for serum myelin basic protein immunoreactivity as a marker of central nervous system lesion and for circulating immunoglobulins and complement (C3) levels. Myelin basic protein concentration did not appear to correlate with tumour type or grade. Serum immunoglobulin levels were found to be within the normal range but the mean IgM level was significantly higher in the glioma group when compared with meningiomas.
D000328:Adult; D001932:Brain Neoplasms / Q000097:blood*; D003176:Complement C3 / Q000032:analysis; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis*; D008297:Male; D004676:Myelin Basic Protein / Q000097:blood*; D011863:Radioimmunoassay; D013120:Spinal Cord Neoplasms / Q000097:blood*
D003176:Complement C3; D007136:Immunoglobulins; D004676:Myelin Basic Protein